Literature DB >> 36274148

Potential contribution of early endothelial progenitor cell (eEPC)-to-macrophage switching in the development of pulmonary plexogenic lesion.

Feng-Jin Shao1,2,3, Xiao-Ling Guo4, Jia-Xue Xu1,5, Rui Liu1,2,3, Dan-Yue Li1, Qing-Hao Li1, Ting Zhou1, Cun Fang1, Xun Tan6,7,8.   

Abstract

BACKGROUND: Plexiform lesions, which have a dynamic appearance in structure and cellular composition, are the histological hallmark of severe pulmonary arterial hypertension in humans. The pathogenesis of the lesion development remains largely unknown, although it may be related to local inflammation and dysfunction in early progenitor endothelial cells (eEPCs). We tested the hypothesis that eEPCs contribute to the development of plexiform lesions by differentiating into macrophages in the setting of chronic inflammation.
METHODS: The eEPC markers CD133 and VEGFR-2, macrophage lineage marker mannose receptor C-type 1 (MRC1), TNFα and nuclear factor erythroid 2-related factor 2 (Nrf2) in plexiform lesions in a broiler model were determined by immunohistochemistry. eEPCs derived from peripheral blood mononuclear cells were exposed to TNFα, and macrophage differentiation and angiogenic capacity of the cells were evaluated by phagocytotic and Matrigel plug assays, respectively. The role of Nrf2 in eEPC-to-macrophage transition as well as in MRC1 expression was also evaluated. Intratracheal installation of TNFα was conducted to determine the effect of local inflammation on the formation of plexiform lesions.
RESULTS: Cells composed of the early lesions have a typical eEPC phenotype whereas those in more mature lesions display molecular and morphological characteristics of macrophages. Increased TNFα production in plexiform lesions was observed with lesion progression. In vitro studies showed that chronic TNFα challenge directed eEPCs to macrophage differentiation accompanied by hyperactivation of Nrf2, a stress-responsive transcription factor. Nrf2 activation (Keap1 knockdown) caused a marked downregulation in CD133 but upregulation in MRC1 mRNA. Dual luciferase reporter assay demonstrated that Nrf2 binds to the promoter of MRC1 to trigger its expression. In good agreement with the in vitro observation, TNFα exposure induced macrophage differentiation of eEPCs in Matrigel plugs, resulting in reduced neovascularization of the plugs. Intratracheal installation of TNFα resulted in a significant increase in plexiform lesion density.
CONCLUSIONS: This work provides evidence suggesting that macrophage differentiation of eEPCs resulting from chronic inflammatory stimulation contributes to the development of plexiform lesions. Given the key role of Nrf2 in the phenotypic switching of eEPCs to macrophages, targeting this molecular might be beneficial for intervention of plexiform lesions.
© 2022. The Author(s).

Entities:  

Keywords:  Endothelial progenitor cells; Inflammation; Keap1; Macrophage; Nuclear factor erythroid 2-related factor 2; Phenotypic switching; Plexiform lesion; Pulmonary arterial hypertension; Pulmonary arterial pressure

Year:  2022        PMID: 36274148     DOI: 10.1186/s12931-022-02210-7

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


  64 in total

1.  Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers. Evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth.

Authors:  C D Cool; J S Stewart; P Werahera; G J Miller; R L Williams; N F Voelkel; R M Tuder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension.

Authors:  Keiko Ohta-Ogo; Hiroyuki Hao; Hatsue Ishibashi-Ueda; Seiichi Hirota; Kazufumi Nakamura; Tohru Ohe; Hiroshi Ito
Journal:  Pathol Int       Date:  2012-01-10       Impact factor: 2.534

3.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension.

Authors:  R M Tuder; B Groves; D B Badesch; N F Voelkel
Journal:  Am J Pathol       Date:  1994-02       Impact factor: 4.307

Review 4.  Bone marrow-derived stem cells and respiratory disease.

Authors:  Carla P Jones; Sara M Rankin
Journal:  Chest       Date:  2011-07       Impact factor: 9.410

5.  Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment.

Authors:  Danny Jonigk; Heiko Golpon; Clemens L Bockmeyer; Lavinia Maegel; Marius M Hoeper; Jens Gottlieb; Nils Nickel; Kais Hussein; Ulrich Maus; Ulrich Lehmann; Sabina Janciauskiene; Tobias Welte; Axel Haverich; Johanna Rische; Hans Kreipe; Florian Laenger
Journal:  Am J Pathol       Date:  2011-05-11       Impact factor: 4.307

6.  Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension.

Authors:  S D Lee; K R Shroyer; N E Markham; C D Cool; N F Voelkel; R M Tuder
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

Review 7.  Cell-based methods for ex vivo evaluation of human endothelial biology.

Authors:  Gian Paolo Fadini; Angelo Avogaro
Journal:  Cardiovasc Res       Date:  2010-04-28       Impact factor: 10.787

8.  Microsatellite instability of endothelial cell growth and apoptosis genes within plexiform lesions in primary pulmonary hypertension.

Authors:  M E Yeager; G R Halley; H A Golpon; N F Voelkel; R M Tuder
Journal:  Circ Res       Date:  2001-01-19       Impact factor: 17.367

9.  Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents.

Authors:  H I Palevsky; B L Schloo; G G Pietra; K T Weber; J S Janicki; E Rubin; A P Fishman
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

10.  Endothelial Progenitor Cells Do Not Originate From the Bone Marrow.

Authors:  Takeshi Fujisawa; Olga Tura-Ceide; Amanda Hunter; Andrew Mitchell; Alex Vesey; Claire Medine; Susan Gallogly; Patrick W F Hadoke; Charlotte Keith; Anne Sproul; Huw Roddie; Grant McQuaker; Ian Wilmut; Nicholas L Mills; Mairi Brittan
Journal:  Circulation       Date:  2019-10-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.